MedPath

The Impact of the Menstrual Cycle on Physical Exercise and Performance

Not Applicable
Recruiting
Conditions
Exercise
Athletic Performance
Menstrual Cycle
Women's Health
Interventions
Other: Periodization of training
Registration Number
NCT05697263
Lead Sponsor
Karolinska Institutet
Brief Summary

The menstrual cycle implies a basic difference in the biology of women and men but the effect of the hormonal variation on training protocols and physical performance is still not fully understood. Despite no existing evidence, the advice to periodize exercise according to the menstrual cycle has been widely spread among elite athletes, coaches, and sports federations. The advice is based on underpowered studies with considerable methodological weaknesses regarding determination of cycle phase, inclusion of athletes and lack of adequate control groups.

The purpose of this randomized, controlled study is to evaluate the effect of exercise periodization on aerobic fitness during different phases of the menstrual cycle. Further, the effect will be related to premenstrual symptoms, body composition and skeletal muscle morphology, sex hormone receptors, metabolic enzymes, and markers of muscle protein synthesis. This study will be well controlled and follow methodology recommendations for menstrual cycle research in sports and exercise.

Female athletes of fertile age will be randomized to different training regimens during three menstrual cycles (12 weeks):

Group A: Training three times a week throughout the menstrual cycle. Group B: Follicular phase-based training five times a week during the follicular phase and thereafter once a week during the luteal phase.

Group C: Luteal phase-based training five times a week during the luteal phase and once a week in the follicular phase.

The exercise will consist of high intensity intermittent spinning classes. Assessment of aerobic fitness and power will be performed at baseline, and again after three completed menstrual cycles. On the same day, body composition will be examined by DXA and blood samples will be collected for analysis of hormones and binding proteins. To confirm menstrual cycle phase, blood samples will be collected for hormone determination, and urinary stick will be used for detection of ovulation. Subjective ratings of menstrual cycle related symptoms will be performed every day. In a subgroup of women, muscle biopsies will be collected from m vastus lateralis at baseline and at the end of the study. This study will contribute to improved knowledge about exercise periodization in relation to the menstrual cycle. Well-grounded data is crucial to give evidence-based recommendations to female athletes when planning their training protocol to optimize training results and performance.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
111
Inclusion Criteria
  • Women exercising at least 3-4 times a week on a high level
  • Regular menstrual cycle with 26-32 cycle days.
  • Fully healthy and be able to follow the training program.
Exclusion Criteria
  • Hormonal contraceptive users,
  • Users of regular medication
  • Chronic disease
  • Past or present neurological disorder
  • Recent musculoskeletal injury

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Follicle phase based trainingPeriodization of trainingFollicular phase-based training five times a week during the follicular phase (the first two weeks of the menstrual cycle) and thereafter once a week for the rest of the cycle.
Luteal phase based trainingPeriodization of trainingLuteal phase-based training five times a week during the luteal phase (from ovulation to next menstruation) and once a week in the follicular phase.
Regular trainingPeriodization of trainingRegular training three times a week throughout the menstrual cycle (control group).
Primary Outcome Measures
NameTimeMethod
Change in aerobic performanceChange from baseline aerobic performance at the end of Cycle 4 (each cycle is around 28 days)

Cosmeds K5 Wearable Metabolic System will be used for breath-by-breath gas exchange measurements. Change in VO2peak from baseline to end of study will be evaluated.

Secondary Outcome Measures
NameTimeMethod
Change in one-leg hop test for distanceChange from baseline test at the end of Cycle 4 (each cycle is around 28 days)

Assessment of functional muscle strength in the lower extremities.

Change in muscle strengthChange from baseline muscle strength at the end of Cycle 4 (each cycle is around 28 days)

A standardized isokinetic device (Biodex®, Corp, Shirley, NY, USA) will be used for measurements of maximal muscle torque (Nm) in the leg extensor muscles at 90 and 120 gr/sec (11). Change in muscle strength from baseline to end of study will be compared between groups.

Change in one-leg sit-to-stand testChange from baseline test at the end of Cycle 4 (each cycle is around 28 days)

Assessment of functional muscle strength in the lower extremities.

Change in body compositionChange from baseline body composition at the end of Cycle 4 (each cycle is around 28 days)

Differences in muscle mass (g), will be determined by DXA (Lunar equipment).

Premenstrual symptomsEvery day during the study period

Prospective ratings of premenstrual symptoms will be performed with the Cyclicity Diagnoser

Change in muscle tissue steroid hormonesChange from baseline muscle tissue steroid hormones at the end of Cycle 4 (each cycle is around 28 days)

Muscle biopsy in mm vastus lateralis

Change in muscle protein synthesisChange from baseline muscle protein synthesis at the end of Cycle 4 (each cycle is around 28 days)

Muscle biopsy in mm vastus lateralis

DysmenorrheaThrough study completion, an average of 4 month

Questionnaire

Change in metabolic serum markersChange from baseline metabolic serum markers at the end of Cycle 4 (each cycle is around 28 days)

Blood samples for analysis of IGF-1.

Change in mucle morphologyChange from baseline muscle morphology at the end of Cycle 4 (each cycle is around 28 days)

Muscle biopsy in mm vastus lateralis

Trial Locations

Locations (1)

Angelica Lindén Hirschberg

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath